BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32780152)

  • 1. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
    Lespessailles E; Chapurlat R
    Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for glucocorticoid-induced osteoporosis.
    Chiodini I; Merlotti D; Falchetti A; Gennari L
    Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
    Tanaka I
    Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
    Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
    Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
    Lems WF; Saag K
    Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
    Kaneko K; Kawai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
    Adami G; Saag KG
    Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid induced osteoporosis.
    Hu K; Adachi JD
    Expert Rev Endocrinol Metab; 2019 Jul; 14(4):259-266. PubMed ID: 31094232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.
    Hayes KN; Baschant U; Hauser B; Burden AM; Winter EM
    Front Endocrinol (Lausanne); 2021; 12():782118. PubMed ID: 34975756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of glucocorticoid-induced osteoporosis.
    Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
    Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
    Bultink IE; Baden M; Lems WF
    Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
    Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
    Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis.
    Leipe J; Holle JU; Weseloh C; Pfeil A; Krüger K
    Z Rheumatol; 2021 Dec; 80(Suppl 2):49-63. PubMed ID: 34705070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [German Society of Rheumatology Recommendations for the management of glucocorticoid-induced Osteoporosis. German version].
    Leipe J; Holle JU; Weseloh C; Pfeil A; Krüger K;
    Z Rheumatol; 2021 Sep; 80(7):670-687. PubMed ID: 34357436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
    Gourlay M; Franceschini N; Sheyn Y
    Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Yuan C; Liang Y; Zhu K; Xie W
    J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is new in the treatment of steroid-induced osteoporosis?
    Liu RH; Werth VP
    Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.